The Role of Anti-PD-1 as a Treatment for Cancer
DOI:
https://doi.org/10.58445/rars.1035Keywords:
anti-PD-1, PD-1, Immune Checkpoint Blockade, Cancer, PDL-1Abstract
Immunotherapy represents a therapeutic strategy to treat various cancers, that involves harnessing one’s immune system to fight cancer. One common type of immunotherapy is anti–PD–1 treatment, which is commonly used in metastatic melanoma patients and patients who suffer from different cancers. In metastatic melanoma, patients typically respond well to anti-PD-1. Unfortunately, patients with other types of cancers such as glioblastoma do not respond as well. Anti-PD-1 may still have a role in tumors such as glioblastoma, but not as a single-agent therapy. Identifying more efficacious combination therapies will be critical to successfully treating these patients.
References
Alexander, W. (2016, March). The Checkpoint Immunotherapy Revolution - PMC. NCBI. Retrieved March 5, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771089/
American Cancer Society. (2022). Cancer Facts & Figures 2022. American Cancer Society. Retrieved March 15, 2024, from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html
Egger, J. V., Lane, M. V., Antonucci, L. A., Dedi, B., & Krucher, N. A. (2016, September 19). Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb. NCBI. Retrieved March 5, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137485/
Eno, J. (2017, November 1). Immunotherapy Through the Years - PMC. NCBI. Retrieved March 15, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188092/
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N., & Ribas, A. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of oncology: official journal of the European Society for Medical Oncology, 30(4), 582–588. https://doi.org/10.1093/annonc/mdz011
Jaoude, D. A., Moore, J. A., Moore, M. B., Twumasi-Ankrah, P., Ablah, E., & Moore, D. F., Jr (2019). Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kansas journal of medicine, 12(3), 65–69.
Lorrey, S., Polania, J. W., Wachsmuth, L. P., Hoyt-Miggelbrink, A., Tritz, Z., Edwards, R., Wolf, D. M., Johnson, A. J., Fecci, P. E., & Ayasoufi, K. (2023). Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege. Neuro-oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad035
Luoyan, A., Antao, X., & Jie, X. (2020). Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 1248, 33-59. 10.1007/978-981-15-3266-5_3.
Moser, J. C., Wei, G., Colonna, S. V., Grossmann, K. F., Patel, S., & Hyngstrom, J. R. (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta oncologica (Stockholm, Sweden), 59(4), 434–437. https://doi.org/10.1080/0284186X.2020.1712473
Pinheiro, S. L. R., Lemos, F. F. B., Marques, H. S., Luz, M. S., De Oliveira Silva, L. G., Santos, C. F. S. M. D., Da Costa Evangelista, K., Calmon, M. S., Loureiro, M. S., & De Melo, F. F. (2023). Immunotherapy in glioblastoma treatment: Current state and future prospects. World Journal of Clinical Oncology, 14(4), 138–159. https://doi.org/10.5306/wjco.v14.i4.138
Raedler, L. A. (2019, June 24). Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma. National Library of Medicine. Retrieved December 19, 2023, from https://dpl6hyzg28thp.cloudfront.net/media/anti-PD1_in_Melanoma.pdf
Yang, T., Kong, Z., & Ma, W. (2020). PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Human Vaccines & Immunotherapeutics, 17(2), 546–553. https://doi.org/10.1080/21645515.2020.1782692
Downloads
Posted
Categories
License
Copyright (c) 2024 Siena Lin
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.